The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF

Inclusion Criteria: * 1.Chronic hepatitis B.(Hepatitis B surface antigen positive for more than 6 months or having evidence of chronic hepatitis B virus infection). * 2.Defined by an acute deterioration in transaminase greater than or equal to 5 times upper normal limit over14 days. * 3.Development of jaundice (serum bilirubin greater than or equal to 10mg/dl). * 4.Development of coagulopathy(PTA≤40% or INR≥1.5 ). * More than one of the 5-8 criteria： * 5.Development of hepatic encephalopathy. * 6.Development of hepatorenal syndrome. * 7.Hepatic narrowing progressively. * 8.Development of massive ascites or peritonitis. * 9\. Willing to provide informed consent and comply with the test requirements Exclusion Criteria: * 1.Patients who have hepatocellular carcinoma confirmed by ultrasound/CT/MR. * 2.Patients who have autoimmune disease (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, etc ) or with abnormal elevation level of autoimmune antibody. * 3.Model for end-stage liver disease (MELD) score \<17 or \>35. * 4.Patients with significant co-morbid illnesses such as cardiovascular or respiratory or intrinsic renal diseases which by themselves may have a bearing on the outcome. * 5.Patients with diseases that researchers consider inappropriate to participate in the study. * 6.Patients who have disseminated intravascular coagulation. * 7.Drug allergy. * 8.Patients with any other contraindications to thymosin alpha1. * 9.Patients who participated in other clinical trials at the same time.